Speakers
Abstract
Abstract Osteoporosis results from aging and hormonal changes represents a major public health concern, particularly in postmenopausal due to estrogen deficiency which is the most common cause of developing osteoporosis. Bisphosphonates have long been considered the first-line treatment for women with post-menopausal osteoporosis in the absence of contraindication. But it only acts as bone resorption inhibitor, that’s why of hydroxy-methyl glutaryl-coenzyme A reductase inhibitors (atorvastatin) provide a promising adjuvant therapy for osteoporosis in addition to treating high cholesterol levels due to dual benefit in the same population. Objectives: This study aimed to investigate whether atorvastatin exert any additional effect on bone mineral density beyond that achieved by alendronate therapy alone in postmenopausal women. Materials and methods: Two study groups (n = 15 postmenopausal women each), all included patients had lumbar spine T-score ≤ -2.5. Group Ⅰ had 10-year ASCVD risk < 5% and received osteoporosis standard therapy (ALD + CA+ VIT D). Group Ⅱ had 10-year ASCVD risk ≥ 5% and received osteoporosis standard therapy (ALD + CA+ VIT D) plus atorvastatin. Lipid profile, hip and spine T-score, BMD measured at baseline and after six months of treatment for each patient. Results: group Ⅱ who received combination therapy had higher increase in hip and spine T-score, and better improvement in hip and spine BMD.The amount of increase in lumbar spine BMD in group Ⅱ was statistically significant in comparison to group Ⅰ who received osteoporosis standard therapy only. Conclusion: Our findings suggest that combination therapy for osteoporosis using atorvastatin in conjunction with alendronate provides superior skeletal benefits compared with standard anti-osteoporotic therapy alone in postmenopausal women.
